A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German) in Healthy Chinese Male Subjects

Trial Profile

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German) in Healthy Chinese Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Shanghai Henlius Biotech
  • Most Recent Events

    • 12 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 24 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top